Beta cells in type 2 diabetes - A crucial contribution to pathogenesis

Diabetes, Obesity and Metabolism

Volumn 10, Issue 5, 2008, Pages 408-420

  Maedler, Kathrin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; GLITAZONE DERIVATIVE; GLUCOSE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PIOGLITAZONE; ROSIGLITAZONE; SALICYLATE SODIUM;

ADIPOCYTE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG MEGADOSE; GLUCOSE INTOLERANCE; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERCORTISOLISM; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PREGNANCY;

EID: 42149108013     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00718.x     Document Type: Article

References (178)

1. Martin-Gronert MS, Ozanne SE. Programming of appetite and type 2 diabetes. Early Hum Dev 2005; 81: 981-988.
2. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
3. Maedler K, Schumann DM, Schulthess F et al. Aging correlates with decreased {beta}-cell proliferative capacity and enhanced sensitivity to apoptosis: A potential role for Fas and pancreatic duodenal homeobox-1. Diabetes 2006; 55: 2455-2462.
4. Steil GM, Trivedi N, Jonas JC et al. Adaptation of beta-cell mass to substrate oversupply: Enhanced function with normal gene expression. Am J Physiol Endocrinol Metab 2001; 280: E788-E796.
5. Hugl SR, White MF, Rhodes CJ. Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem 1998; 273: 17771-17779.
6. Leahy JL, Bumbalo LM, Chen C. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 1994; 43: 173-179.
7. Sako Y, Grill VE. Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 1990; 39: 1580-1583.
8. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985; 28: 119-121.
9. Leahy JL, Cooper HE, Deal DA, Weir GC. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest 1986; 77: 908-915.
10. Leahy JL, Weir GC. Evolution of abnormal insulin secretory responses during 48-h in vivo hyperglycemia. Diabetes 1988; 37: 217-222.
11. Robertson RP. Type II diabetes, glucose "non-sense,"and islet desensitization. Diabetes 1989; 38: 1501-1505.
12. Srinivasan S, Bernal-Mizrachi E, Ohsugi M, Permutt MA. Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. Am J Physiol Endocrinol Metab 2002; 283: E784-E793.
13. Maedler K, Spinas GA, Lehmann R et al. Glucose induces beta-cell apoptosis via upregulation of the Fas-receptor in human islets. Diabetes 2001; 50: 1683-1690.
14. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-630.
15. Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15: 442-455.
16. Kaiser N, Corcos AP, Sarel I, Cerasi E. Monolayer culture of adult rat pancreatic islets on extracellular matrix: Modulation of B-cell function by chronic exposure to high glucose. Endocrinology 1991; 129: 2067-2076.
17. Eizirik DL, Korbutt GS, Hellerstrom C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J Clin Invest 1992; 90: 1263-1268.
18. Ling Z, Kiekens R, Mahler T et al. Effects of chronically elevated glucose levels on the functional properties of rat pancreatic beta-cells. Diabetes 1996; 45: 1774-1782.
19. Marshak S, Leibowitz G, Bertuzzi F et al. Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 1999; 48: 1230-1236.
20. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: Indirect evidence for islet regeneration? Diabetologia 2005; 48: 2221-2228.
21. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 1999; 48: 738-744.
22. Federici M, Hribal M, Perego L et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: A potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 2001; 50: 1290-1301.
23. Efanova IB, Zaitsev SV, Zhivotovsky B et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 1998; 273: 33501-33507.
24. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY. Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 2001; 50: 69-76.
25. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
26. Maedler K, Schumann DM, Sauter N et al. Low concentration of interleukin-1{beta} induces FLICE-inhibitory protein-mediated {beta}-cell proliferation in human pancreatic islets. Diabetes 2006; 55: 2713-2722.
27. Tajiri Y, Moller C, Grill V. Long-term effects of aminoguanidine on insulin release and biosynthesis: Evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology 1997; 138: 273-280.
28. Kaneto H, Kawamori D, Nakatani Y, Gorogawa S, Matsuoka TA. Oxidative stress and the JNK pathway as a potential therapeutic target for diabetes. Drug News Perspect 2004; 17: 447-453.
29. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 (Suppl. 1): S119-S124.
30. Briaud I, Lingohr MK, Dickson LM, Wrede CE, Rhodes CJ. Differential activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic beta-cells. Diabetes 2003; 52: 974-983.
31. Maedler K, Storling J, Sturis J et al. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004; 53: 1706-1713.
32. Arnette D, Gibson TB, Lawrence MC et al. Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells. J Biol Chem 2003; 278: 32517-32525.
33. Khoo S, Cobb MH. Activation of mitogen-activating protein kinase by glucose is not required for insulin secretion. Proc Natl Acad Sci U S A 1997; 94: 5599-5604.
34. Khoo S, Gibson TB, Arnette D et al. MAP kinases and their roles in pancreatic beta-cells. Cell Biochem Biophys 2004; 40: 191-200.
35. Sprinkel AM, Andersen NA, Mandrup-Poulsen T. Glucose potentiates interleukin-1b (IL-1b)-induced p38 mitogen-activated protein kinase activity in rat pancreatic islets of Langerhans. Eur Cytokine Netw 2001; 12: 331.
36. Benes C, Roisin MP, Van Tan H, Creuzet C, Miyazaki J, Fagard R. Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line. J Biol Chem 1998; 273: 15507-15513.
37. Dickson LM, Lingohr MK, McCuaig J et al. Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). J Biol Chem 2001; 276: 21110-21120.
38. Frodin M, Sekine N, Roche E et al. Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting beta-cell line, INS-1. J Biol Chem 1995; 270: 7882-7889.
39. Lingohr MK, Dickson LM, McCuaig JF, Hugl SR, Twardzik DR, Rhodes CJ. Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes 2002; 51: 966-976.
40. Robertson RP, Olson LK, Zhang HJ. Differentiating glucose toxicity from glucose desensitization: A new message from the insulin gene. Diabetes 1994; 43: 1085-1089.
41. Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J Clin Invest 1992; 90: 320-325.
42. Wang H, Kouri G, Wollheim CB. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J Cell Sci 2005; 118: 3905-3915.
43. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-506.
44. Mohanty S, Spinas GA, Maedler K et al. Overexpression of IRS2 in isolated pancreatic islets causes proliferation and protects human beta-cells from hyperglycemia-induced apoptosis. Exp Cell Res 2005; 303: 68-78.
45. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol (Copenh) 1988; 118: 365-373.
46. Andrews WJ, Vasquez B, Nagulesparan M et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984; 33: 634-642.
47. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222-234.
48. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356.
49. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-1032.
50. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol (Copenh) 1967; 55: 330-345.
51. Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 1994; 43: 735-740.
52. Gerich JE. Insulin resistance is not necessarily an essential component of type 2 diabetes. J Clin Endocrinol Metab 2000; 85: 2113-2115.
53. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol 2000; 24: 297-302.
54. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002; 45: 85-96.
55. Yoon KH, Ko SH, Cho JH et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-2308.
56. Mathis D, Vence L, Benoist C. Beta-cell death during progression to diabetes. Nature 2001; 414: 792-798.
57. Eizirik DL, Mandrup-Poulsen T. A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133.
58. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
59. Loweth AC, Williams GT, James RF, Scarpello JH, Morgan NG. Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1beta and Fas ligation. Diabetes 1998; 47: 727-732.
60. Moriwaki M, Itoh N, Miyagawa J et al. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset type I diabetes mellitus. Diabetologia 1999; 42: 1332-1340.
61. Liu D, Pavlovic D, Chen MC, Flodstrom M, Sandler S, Eizirik DL. Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). Diabetes 2000; 49: 1116-1122.
62. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa F, Inada C, Nonaka K. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996; 39: 1306-1312.
63. Riachy R, Vandewalle B, Moerman E et al. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006; 11: 151-159.
64. Allison J, Thomas HE, Catterall T, Kay TW, Strasser A. Transgenic expression of dominant-negative Fas-associated death domain protein in beta cells protects against Fas ligand-induced apoptosis and reduces spontaneous diabetes in nonobese diabetic mice. J Immunol 2005; 175: 293-301.
65. Chervonsky AV, Wang Y, Wong FS et al. The role of Fas in autoimmune diabetes. Cell 1997; 89: 17-24.
66. Thomas HE, Darwiche R, Corbett JA, Kay TW. Evidence that beta cell death in the nonobese diabetic mouse is Fas independent. J Immunol 1999; 163: 1562-1569.
67. Nolsoe RL, Hamid YH, Pociot F et al. Association of a microsatellite in FASL to type II diabetes and of the FAS-670G>A genotype to insulin resistance. Genes Immun 2006; 7: 316-321.
68. Hoorens A, Van dC, Kloppel G, Pipeleers D. Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program. J Clin Invest 1996; 98: 1568-1574.
69. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195.
70. Maedler K, Fontana A, Ris F et al. FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication. Proc Natl Acad Sci U S A 2002; 99: 8236-8241.
71. Cottet S, Dupraz P, Hamburger F, Dolci W, Jaquet M, Thorens B. cFLIP protein prevents tumor necrosis factor-alpha-mediated induction of caspase-8-dependent apoptosis in insulin-secreting betaTc-Tet cells. Diabetes 2002; 51: 1805-1814.
72. Fenjves ES, Ochoa MS, Gay-Rabinstein C, Ricordi C, Curran MA. Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: Implications for islet transplantation. Cell Transplant 2004; 13: 489-496.
73. Schumann DM, Maedler K, Franklin I et al. The Fas pathway is involved in beta-cell secretory function. Proc Natl Acad Sci U S A 2007.
74. Liadis N, Salmena L, Zhu X et al. Tissue specific role of caspase-8 in beta-cell homeostasis. Diabetes 2005; 54 (Suppl. 1): A77, 312.
75. Hanke J. Apoptosis and occurrence of bcl-2, bak, bax, fas and FasL in the developing and adult rat endocrine pancreas [In Process Citation]. Anat Embryol (Berl) 2000; 202: 303-312.
76. Kaur V. Age-dependent changes in PDX-1 regulation and pancreatic beta cell function. Diabetes 2005; 54 (Suppl. 1): A404.
77. Ihm SH, Matsumoto I, Sawada T et al. Effect of donor age on function of isolated human islets. Diabetes 2006; 55: 1361-1368.
78. Kwon G, Corbett JA, Rodi CP, Sullivan P, McDaniel ML. Interleukin-1 beta-induced nitric oxide synthase expression by rat pancreatic beta-cells: Evidence for the involvement of nuclear factor kappa B in the signaling mechanism. Endocrinology 1995; 136: 4790-4795.
79. Darville MI, Eizirik DL. Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-kappaB and C/EBP. Diabetes 2001; 50: 1741-1748.
80. Flodstrom M, Welsh N, Eizirik DL. Cytokines activate the nuclear factor kappa B (NF-kappa B) and induce nitric oxide production in human pancreatic islets. FEBS Lett 1996; 385: 4-6.
81. Karin M. How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867-6874.
82. Bernal-Mizrachi E, Wen W, Shornick M, Permutt MA. Activation of nuclear factor-kappaB by depolarization and Ca(2+) influx in MIN6 insulinoma cells. Diabetes 2002; 51 (Suppl. 3): S484-S488.
83. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA. Pioglitazone and sodium salicylate protect human {beta}-cells against apoptosis and impaired function induced by glucose and interleukin-1β. J Clin Endocrinol Metab 2004; 89: 5059-5066.
84. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): A new model for type 2 diabetes. Diabetes 2004; 53: 1509-1516.
85. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 2005; 90: 6678-6686.
86. Heimberg H, Heremans Y, Jobin C et al. Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis. Diabetes 2001; 50: 2219-2224.
87. Norlin S, Ahlgren U, Edlund H. Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion. Diabetes 2005; 54: 125-132.
88. Eldor R, Yeffet A, Baum K et al. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci U S A 2006; 103: 5072-5077.
89. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/ NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003; 27 (Suppl. 3): S49-S52.
90. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: Novel blockers of beta-cell death. Diabetes 2001; 50: 77-82.
91. Sandberg JO, Eizirik DL, Sandler S. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 1997; 108: 314-317.
92. Sandberg JO, Eizirik DL, Sandler S, Tracey DE, Andersson A. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes 1993; 42: 1845-1851.
93. Ebstein W. Zur Therapie des Diabetes Mellitus, insbesondere über die Anwendung des Salicylsauren Natron bei demselben. Berliner Klinische Wochenschrift 1876; 24: 337-340.
94. Robertson RP, Chen M. Modulation of insulin secretion in normal and diabetic humans by prostaglandin E and sodium salicylate. Trans Assoc Am Physicians 1977; 90: 353-365.
95. Hundal RS, Petersen KF, Mayerson AB et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326.
96. Tran PO, Gleason CE, Robertson RP. Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function. Diabetes 2002; 51: 1772-1778.
97. Robertson RP, Tsai P, Little SA, Zhang HJ, Walseth TF. Receptor-mediated adenylate cyclase-coupled mechanism for PGE2 inhibition of insulin secretion in HIT cells. Diabetes 1987; 36: 1047-1053.
98. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-1677.
99. Thomas T, Nadackal GT, Thomas K. Aspirin and diabetes: Inhibition of amylin aggregation by nonsteroidal anti-inflammatory drugs. Exp Clin Endocrinol Diabetes 2003; 111: 8-11.
100. Kwon G, Hill JR, Corbett JA, McDaniel ML. Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Mol Pharmacol 1997; 52: 398-405.
101. Elouil H, Cardozo AK, Eizirik DL, Henquin JC, Jonas JC. High glucose and hydrogen peroxide increase c-Myc and haeme-oxygenase 1 mRNA levels in rat pancreatic islets without activating NFkappaB. Diabetologia 2005; 48: 496-505.
102. Matsui J, Terauchi Y, Kubota N, et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes 2004; 53: 2844-2854.
103. Halliwell B. Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? Lancet 1994; 344: 721-724.
104. Rabinovitch A, Suarez WL, Power RF. Combination therapy with an antioxidant and a corticosteroid prevents autoimmune diabetes in NOD mice. Life Sci 1992; 51: 1937-1943.
105. Sumoski W, Baquerizo H, Rabinovitch A. Oxygen free radical scavengers protect rat islet cells from damage by cytokines. Diabetologia 1989; 32: 792-796.
106. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997; 46: 1733-1742.
107. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029.
108. Donath MY, Ehses JA, Maedler K et al. Mechanisms of β-cell death in type 2 diabetes. Diabetes 2005; 54 (Suppl. 2): S108-S113.
109. Mine T, Miura K, Okutsu T, Mitsui A, Kitahara Y. Gene expression profile in the pancreatic islets of Goto-Kakizaki (GK) rats with repeated postprandial hyperglycemia. Diabetes 2004; 53 (Suppl. 2): 2475A.
110. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
111. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: A link between type 1 and type 2 diabetes. J Mol Med 2003; 81: 455-470.
112. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232: 1545-1547.
113. Corbett JA, Lancaster JR Jr, Sweetland MA, McDaniel ML. Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-1 beta-induced inhibition of insulin secretion. J Biol Chem 1991; 266: 21351-21354.
114. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986; 29: 63-67.
115. Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 1985; 40: 424-429.
116. Spinas GA, Mandrup-Poulsen T, Molvig J et al. Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. Acta Endocrinol (Copenh) 1986; 113: 551-558.
117. Giannoukakis N, Mi Z, Rudert WA, Gambotto A, Trucco M, Robbins P. Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I. Gene Ther 2000; 7: 2015-2022.
118. Giannoukakis N, Rudert WA, Ghivizzani SC et al. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999; 48: 1730-1736.
119. Rabinovitch A, Sumoski W, Rajotte RV, Warnock GL. Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab 1990; 71: 152-156.
120. Stassi G, De Maria R, Trucco G et al. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186: 1193-1200.
121. Spinas GA, Hansen BS, Linde S et al. Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans. Diabetologia 1987; 30: 474-480.
122. Spinas GA, Palmer JP, Mandrup-Poulsen T, Andersen H, Nielsen JH, Nerup J. The bimodal effect of interleukin 1 on rat pancreatic beta-cells -stimulation followed by inhibition -depends upon dose, duration of exposure, and ambient glucose concentration. Acta Endocrinol (Copenh) 1988; 119: 307-311.
123. Satoh J, Seino H, Abo T et al. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989; 84: 1345-1348.
124. Satoh J, Seino H, Shintani S et al. Inhibition of type 1 diabetes in BB rats with recombinant human tumor necrosis factor-alpha. J Immunol 1990; 145: 1395-1399.
125. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A 1990; 87: 968-972.
126. Wilson CA, Jacobs C, Baker P et al. IL-1 beta modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J Immunol 1990; 144: 3784-3788.
127. Zunino SJ, Simons LF, Sambrook JF, Gething MJ. Interleukin-1 promotes hyperglycemia and insulitis in mice normally resistant to streptozotocin-induced diabetes. Am J Pathol 1994; 145: 661-670.
128. del Rey A, Besedovsky H. Antidiabetic effects of interleukin 1. Proc Natl Acad Sci U S A 1989; 86: 5943-5947.
129. Maedler K, Schumann DM, Sauter N et al. The physiological role of IL-1b is mediated by IL-1Ra secretion of human pancreatic islets. Diabetes 2005; 54 (Suppl. 1): A387.
130. Corkey BE, Geschwind JF, Deeney JT, Hale DE, Douglas SD, Kilpatrick L. Ca2+ responses to interleukin 1 and tumor necrosis factor in cultured human skin fibroblasts. Possible implications for Reye syndrome. J Clin Invest 1991; 87: 778-786.
131. Stoffels K, Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C. Interleukin-1 receptor antagonist inhibits primary non-function and prolongs graft survival time of xenogeneic islets transplanted in sponaeously diabetic autoimmune NOD mice. Diabetologia 2002; 45 (Suppl. 2): 424.
132. Tellez N, Montolio M, Biarnes M, Castano E, Soler J, Montanya E. Adenoviral overexpression of interleukin-1 receptor antagonist protein increases beta-cell replication in rat pancreatic islets. Gene Ther 2005; 12: 120-128.
133. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 2000; 59 (Suppl. 1): I60-i64.
134. Sandberg JO, Andersson A, Eizirik DL, Sandler S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 1994; 202: 543-548.
135. Nicoletti F, Di Marco R, Barcellini W et al. Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol 1994; 24: 1843-1847.
136. Maedler K, Sergeev P, Ehses JA et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 2004; 101: 8138-8143.
137. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: A possible link to the resistance to leptin? J Clin Endocrinol Metab 2002; 87: 1184-1188.
138. Marculescu R, Endler G, Schillinger M et al. Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. Diabetes 2002; 51: 3582-3585.
139. Sauter NS, Schulthess FT, Donath MY, Maedler K. The anti-inflammatory cytokine IL-1Ra protects from nutrition-induced hyperglycemia and glucose tolerance. Diabetologia 2006; 49: 310.
140. Donath MY, Faulenbach M, Larsen CM, Vaag A, Mandrup-Poulsen T. Treatment with IL-1 receptor antagonist improves glycemic control and β-cell function in patients with type 2 diabetes. Diabetologia 2006; 49: 160.
141. Koerner A, Kratzsch J, Kiess W. Adipocytokines: Leptin -the classical, resistin -the controversical, adiponectin -the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525-546.
142. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: More than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450.
143. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020-1024.
144. Walker KZ, O'Dea K, Johnson L et al. Body fat distribution and non-insulin-dependent diabetes: Comparison of a fiber-rich, high-carbohydrate, low-fat (23%) diet and a 35% fat diet high in monounsaturated fat [see comments]. Am J Clin Nutr 1996; 63: 254-260.
145. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: Role of metabolic and genetic abnormalities. Am J Med 2002; 113 (Suppl. 6A): 3S-11S.
146. Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003; 52: 726-733.
147. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-138.
148. Randle PJ, Garland PB, Newsholme EA, Hales CN. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 1965; 131: 324-333.
149. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44: 863-870.
150. Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis 2002; 7: 335-345.
151. Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A. Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology 2006; 147: 3398-3407.
152. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes -a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-342.
153. Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: Role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002; 51 (Suppl. 3): S405-S413.
154. Muoio DM, Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 2002; 16: 653-666.
155. Roduit R, Thorens B. Inhibition of glucose-induced insulin secretion by long-term preexposure of pancreatic islets to leptin. FEBS Lett 1997; 415: 179-182.
156. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.
157. Matarese G, Sanna V, Lechler RI et al. Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes 2002; 51: 1356-1361.
158. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
159. Maffei M, Halaas J, Ravussin E et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-1161.
160. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004; 53 (Suppl. 1): S152-S158.
161. Schmidt MI, Duncan BB, Vigo A et al. Leptin and incident type 2 diabetes: Risk or protection? Diabetologia 2006; 49: 2086-2096.
162. Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 1997; 46: 313-316.
163. Kulkarni RN, Wang ZL, Wang RM et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest 1997; 100: 2729-2736
164. Pallett AL, Morton NM, Cawthorne MA, Emilsson V. Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem Biophys Res Commun 1997; 238: 267-270.
165. Seufert J, Kieffer TJ, Leech CA et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 670-676.
166. Shimabukuro M, Wang MY, Zhou YT, Newgard CB, Unger RH. Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A 1998; 95: 9558-9561.
167. Koyama K, Chen G, Wang MY et al. Beta-cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy. Diabetes 1997; 46: 1276-1280.
168. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561-564.
169. Patel L, Buckels AC, Kinghorn IJ et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-476.
170. Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 2002; 530: 158-162.
171. Minn AH, Patterson NB, Pack S et al. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 2003; 310: 641-645.
172. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
173. Rea R, Donnelly R. Resistin: An adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 2004; 6: 163-170.
174. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-5795.
175. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
176. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.
177. Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J. Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 2004; 47: 249-258.
178. Staiger K, Stefan N, Staiger H et al. Adiponectin is functionally active in human islets but does not affect insulin secretory function or beta-cell lipoapoptosis. J Clin Endocrinol Metab 2005; 90: 6707-6713.